HOW IT WORKS

PHOENIX concept & service strategies

PHOENIX creates a Single Entry Point to facilities, technologies, services and expertise for all technology transfer aspects from characterization, testing, verification up to scale up, GMP compliant manufacturing and regulatory guidance.



PHOENIX will develop and establish new facilities and upgrade existing ones to make them available to SMEs, start-ups and research laboratories for scale-up, GMP production and testing of nano-pharmaceuticals. The services and expertise provided by the OITB will include production and characterisation under GMP conditions, safety evaluation, regulatory compliance and commercialisation boost.

OUR TEAM

The PHOENIX team consists of 12 international partners distributed across 6 countries.

The partners are from the following countries: Austria, Croatia, Germany, Luxembourg, Netherlands and Spain. All partners contribute actively to the project, ensuring the flow of ideas and projects results to the wider community.

LIST · MyBiotech · NANOMOL TECHNOLOGIES · Leanbio Pro · BNN · CSIC · imi · RCPE · Cenya Imaging · Topas Therapeutics · grace bio · RECENDT

GET IN TOUCH.

info@phoenix-oitb.eu

Phoenix

Pharmaceutical Open Innovation Test Bed for Enabling Nano-pharmaceutical Innovative Products

To learn more visit:
www.phoenix-oitb.eu

PHOENIX project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953110.

DEMO CASES

Demonstrating scalability from prototype to industrial manufacturing

To test the operative capacity of PHOENIX-OITB, five demo-cases representative of five different nano-pharmaceutical types, four different manufacturing methods and three different administration routes will be employed to demonstrate and verify the PHOENIX technologies in an industrially relevant environment.

1. **Polymer-based diagnostic agent**
2. **Polymeric particle conjugates loaded with small peptides**
3. **Oral formulation of nanocrystals**
4. **Nanoliposomes loaded with an enzyme for intravenous administration**
5. **Antimicrobial nanovesicles for topical administration**

OUR OBJECTIVES

Transfer nano-pharmaceuticals from lab bench to clinical trials

We aim to enable the seamless, timely and cost-friendly transfer of nano-pharmaceuticals from lab bench to clinical trials by providing the necessary advanced, affordable and easily accessible PHOENIX-OITB.

Objective 1 - Creation of a "single-entry point" (SEP) for nano-pharmaceuticals

Objective 2 - Finding solutions for the important hurdle in the translational process of most nano-pharmaceuticals - the so-called "innovation valley of death" situation

Objective 3 - One-stop shopping for GMP

Objective 4 - Establishment of a PQMS able to tackle regulatory, economic, organisational and technical aspects of risk/benefit (R/B) ratio assessment

Objective 5 - Launching PHOENIX Quality-by-Design (QbD), Safe-by-Design (SbD) and Sustainability-by-Design (Sus-b-D) concepts matching the pharmaceutical industry needs

Objective 6 - Assessment and demonstration of PHOENIX applicability in relevant industrial environments by means of five demo-cases (initial TRL≥4)

Objective 7 - Achieving PHOENIX financial sustainability

WORK PLAN

Implementing ideas into action



WP1: Overall Sustainability & Business Development (Exploitation) of the PHOENIX-OITB association

WP2: Quality Management

WP3: Research and Development

WP4: Production (Chemistry, Manufacturing, Control – CMC)

WP5: Regulatory Support

WP6: Marketing (Dissemination & Communication)

WP7: Project Management and Coordination